Utilization and costs of glucose lowering therapies following health technology assessment for the new reimbursement scheme in Sweden

A new reimbursement scheme (RS) for glucose lowering therapies (GLT) was implemented in Sweden on March 1, 2010. Products on the market were retained, restricted, excluded or excluded for new courses in the new RS. The aim of this study was to compare utilization and costs of GLT for type 2 diabetes Mellitus (T2DM) before and after the implementation of the changed RS.

MoreLess

Year of publication:	2012
Authors:	Pettersson, Billie ; Hoffmann, Mikael ; Andersson, David ; Wändell, Per ; Levin, Lars-Åke
Published in:	Health Policy. - Elsevier, ISSN 0168-8510. - Vol. 108.2012, 2, p. 207-215
Publisher:	Elsevier
Subject:	Pricing and reimbursement policy \| Glucose lowering therapies \| Drug utilization \| Health technology assessment \| Health economics

More details

Type of publication:	Article
Source:	RePEc - Research Papers in Economics

Persistent link: https://www.econbiz.de/10011048419